Pauline Charbogne1, Olivier Gardon2, Elena Martín-García3, Helen L Keyworth4, Aya Matsui5, Anna E Mechling6, Thomas Bienert7, Md Taufiq Nasseef8, Anne Robé2, Luc Moquin8, Emmanuel Darcq8, Sami Ben Hamida8, Patricia Robledo3, Audrey Matifas2, Katia Befort9, Claire Gavériaux-Ruff2, Laura-Adela Harsan10, Dominik von Elverfeldt7, Jurgen Hennig7, Alain Gratton8, Ian Kitchen4, Alexis Bailey11, Veronica A Alvarez5, Rafael Maldonado3, Brigitte L Kieffer12. 1. Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch; Douglas Mental Health Institute, Department of Psychiatry, McGill University, Montreal, Quebec, Canada. 2. Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch. 3. Departament de Ciencies Experimentals i de la Salut, Universitat Pompeu Fabra, PRBB, Barcelona, Spain. 4. Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, United Kingdom. 5. Section on Neuronal Structure, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland. 6. Department of Radiology, Medical Physics, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany; Faculty of Biology, University of Freiburg, Freiburg, Germany. 7. Department of Radiology, Medical Physics, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany. 8. Douglas Mental Health Institute, Department of Psychiatry, McGill University, Montreal, Quebec, Canada. 9. Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch; Laboratoire de Neurosciences Cognitives et Adaptatives, Université de Strasbourg Faculté de Psychologie, Strasbourg, France; Laboratoire de Neurosciences Cognitives et Adaptatives, UMR 7364, Centre National de la Recherche Scientifique, Strasbourg, France. 10. Laboratory of Engineering, Informatics and Imaging, Integrative Multimodal Imaging in Healthcare, UMR 7357, University of Strasbourg, Strasbourg, France; University Hospital Strasbourg, Department of Biophysics and Nuclear Medicine, Strasbourg, France; Department of Radiology, Medical Physics, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany. 11. Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, United Kingdom; Institute of Medical and Biomedical Education, St. George's University of London, London, United Kingdom. 12. Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch; Douglas Mental Health Institute, Department of Psychiatry, McGill University, Montreal, Quebec, Canada. Electronic address: brigitte.kieffer@douglas.mcgill.ca.
Abstract
BACKGROUND: Mu opioid receptors (MORs) are central to pain control, drug reward, and addictive behaviors, but underlying circuit mechanisms have been poorly explored by genetic approaches. Here we investigate the contribution of MORs expressed in gamma-aminobutyric acidergic forebrain neurons to major biological effects of opiates, and also challenge the canonical disinhibition model of opiate reward. METHODS: We used Dlx5/6-mediated recombination to create conditional Oprm1 mice in gamma-aminobutyric acidergic forebrain neurons. We characterized the genetic deletion by histology, electrophysiology, and microdialysis; probed neuronal activation by c-Fos immunohistochemistry and resting-state functional magnetic resonance imaging; and investigated main behavioral responses to opiates, including motivation to obtain heroin and palatable food. RESULTS: Mutant mice showed MOR transcript deletion mainly in the striatum. In the ventral tegmental area, local MOR activity was intact, and reduced activity was only observed at the level of striatonigral afferents. Heroin-induced neuronal activation was modified at both sites, and whole-brain functional networks were altered in live animals. Morphine analgesia was not altered, and neither was physical dependence to chronic morphine. In contrast, locomotor effects of heroin were abolished, and heroin-induced catalepsy was increased. Place preference to heroin was not modified, but remarkably, motivation to obtain heroin and palatable food was enhanced in operant self-administration procedures. CONCLUSIONS: Our study reveals dissociable MOR functions across mesocorticolimbic networks. Thus, beyond a well-established role in reward processing, operating at the level of local ventral tegmental area neurons, MORs also moderate motivation for appetitive stimuli within forebrain circuits that drive motivated behaviors.
BACKGROUND: Mu opioid receptors (MORs) are central to pain control, drug reward, and addictive behaviors, but underlying circuit mechanisms have been poorly explored by genetic approaches. Here we investigate the contribution of MORs expressed in gamma-aminobutyric acidergic forebrain neurons to major biological effects of opiates, and also challenge the canonical disinhibition model of opiate reward. METHODS: We used Dlx5/6-mediated recombination to create conditional Oprm1mice in gamma-aminobutyric acidergic forebrain neurons. We characterized the genetic deletion by histology, electrophysiology, and microdialysis; probed neuronal activation by c-Fos immunohistochemistry and resting-state functional magnetic resonance imaging; and investigated main behavioral responses to opiates, including motivation to obtain heroin and palatable food. RESULTS: Mutant mice showed MOR transcript deletion mainly in the striatum. In the ventral tegmental area, local MOR activity was intact, and reduced activity was only observed at the level of striatonigral afferents. Heroin-induced neuronal activation was modified at both sites, and whole-brain functional networks were altered in live animals. Morphineanalgesia was not altered, and neither was physical dependence to chronic morphine. In contrast, locomotor effects of heroin were abolished, and heroin-induced catalepsy was increased. Place preference to heroin was not modified, but remarkably, motivation to obtain heroin and palatable food was enhanced in operant self-administration procedures. CONCLUSIONS: Our study reveals dissociable MOR functions across mesocorticolimbic networks. Thus, beyond a well-established role in reward processing, operating at the level of local ventral tegmental area neurons, MORs also moderate motivation for appetitive stimuli within forebrain circuits that drive motivated behaviors.
Authors: Anna E Mechling; Neele S Hübner; Hsu-Lei Lee; Jürgen Hennig; Dominik von Elverfeldt; Laura-Adela Harsan Journal: Neuroimage Date: 2014-04-06 Impact factor: 6.556
Authors: Joanes Grandjean; Carola Canella; Cynthia Anckaerts; Gülebru Ayrancı; Salma Bougacha; Thomas Bienert; David Buehlmann; Ludovico Coletta; Daniel Gallino; Natalia Gass; Clément M Garin; Nachiket Abhay Nadkarni; Neele S Hübner; Meltem Karatas; Yuji Komaki; Silke Kreitz; Francesca Mandino; Anna E Mechling; Chika Sato; Katja Sauer; Disha Shah; Sandra Strobelt; Norio Takata; Isabel Wank; Tong Wu; Noriaki Yahata; Ling Yun Yeow; Yohan Yee; Ichio Aoki; M Mallar Chakravarty; Wei-Tang Chang; Marc Dhenain; Dominik von Elverfeldt; Laura-Adela Harsan; Andreas Hess; Tianzi Jiang; Georgios A Keliris; Jason P Lerch; Andreas Meyer-Lindenberg; Hideyuki Okano; Markus Rudin; Alexander Sartorius; Annemie Van der Linden; Marleen Verhoye; Wolfgang Weber-Fahr; Nicole Wenderoth; Valerio Zerbi; Alessandro Gozzi Journal: Neuroimage Date: 2019-10-12 Impact factor: 6.556
Authors: Kirsten A Porter-Stransky; Alyssa K Petko; Saumya L Karne; L Cameron Liles; Nikhil M Urs; Marc G Caron; Carlos A Paladini; David Weinshenker Journal: Addict Biol Date: 2019-08-23 Impact factor: 4.280
Authors: L J Boulos; S Ben Hamida; J Bailly; M Maitra; A T Ehrlich; C Gavériaux-Ruff; E Darcq; B L Kieffer Journal: Neuropsychopharmacology Date: 2019-04-20 Impact factor: 7.853
Authors: Miriam Martínez-Navarro; David Cabañero; Agnieszka Wawrzczak-Bargiela; Anne Robe; Claire Gavériaux-Ruff; Brigitte L Kieffer; Ryszard Przewlocki; Josep E Baños; Rafael Maldonado Journal: Br J Pharmacol Date: 2020-02-10 Impact factor: 8.739